JAKs or better: Q32 ups ante in AA with IL-7 antibody phase II
· randy osborne
AI Briefing
- • Q32 Bio Inc. shares skyrocket 90.7% to $21.38 after announcing IL-7 antibody phase II results.
- • The company's treatment shows clinically proven promise, rivaling JAK inhibitors in efficacy.
- • Q32 Bio's shares close at $21.38, up $10.17 from the previous day's close.
Context
Q32 Bio Inc's shares closed at $21.38 on July 13, a significant increase of $10.17 or 90.7%. The company's stock surge is related to its work on an alopecia drug.
The development of this drug is significant because it may offer a safer alternative to JAK inhibitors, which carry black box warnings, while still providing powerful efficacy.
Advertisement